Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Operations (2016 - 2025)

China Pharma Holdings' Cash from Operations history spans 16 years, with the latest figure at 73729.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 75.32% year-over-year to 73729.0; the TTM value through Dec 2025 reached 70000.0, up 117.24%, while the annual FY2025 figure was 70000.0, 117.24% up from the prior year.
  • Cash from Operations reached 73729.0 in Q4 2025 per CPHI's latest filing, up from 236987.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1007286.0 in Q3 2023 to a low of 1468214.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 84756.6, with a median of 66363.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: skyrocketed 1438.41% in 2024, then plummeted 404.74% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 198112.0 in 2021, then surged by 395.08% to 584594.0 in 2022, then crashed by 103.82% to 22323.0 in 2023, then surged by 1438.41% to 298773.0 in 2024, then tumbled by 75.32% to 73729.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Cash from Operations are 73729.0 (Q4 2025), 236987.0 (Q3 2025), and 293258.0 (Q2 2025).